Mechanisms of Resistance to EGFR TKIs and Development of a New Generation of Drugs in Non-Small-Cell Lung Cancer

Gefitinib and erlotinib, which are epidermal growth factor receptor- (EGFR-) specific tyrosine kinase inhibitors (TKIs), are widely used as molecularly targeted drugs for non-small-cell lung cancer (NSCLC). Currently, the search for EGFR gene mutations is becoming essential for the treatment of NSCL...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Kosaka, Takayuki, Yamaki, Ei, Mogi, Akira, Kuwano, Hiroyuki
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Hindawi Publishing Corporation 2011
Gaiak:
Review Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3114474/
https://ncbi.nlm.nih.gov/pubmed/21687596
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2011/165214
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak